Ever Supreme Bio Technology Co., Ltd (TPEX:6712)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
169.00
-4.50 (-2.59%)
Mar 31, 2025, 1:30 PM CST
-14.33%
Market Cap 13.78B
Revenue (ttm) 844.86M
Net Income (ttm) 254.33M
Shares Out 81.56M
EPS (ttm) 3.15
PE Ratio 53.73
Forward PE 36.11
Dividend 5.45 (3.14%)
Ex-Dividend Date May 29, 2024
Volume 505,735
Average Volume 204,661
Open 170.00
Previous Close 173.50
Day's Range 168.00 - 171.50
52-Week Range 166.00 - 215.00
Beta 0.32
RSI 26.38
Earnings Date Mar 28, 2025

About TPEX:6712

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6712
Full Company Profile

Financial Performance

In 2023, TPEX:6712's revenue was 758.39 million, an increase of 20.86% compared to the previous year's 627.51 million. Earnings were 539.40 million, an increase of 168.74%.

Financial Statements

News

There is no news available yet.